News

Ambarella, Inc. Achieves Significant Growth in Q2 2026

Ambarella, Inc. Achieves Significant Growth in Q2 2026

Ambarella, Inc. Financial Highlights for Second Quarter Fiscal Year 2026

Ambarella, Inc. (NASDAQ: AMBA), a leader in edge AI semiconductor technology, revealed impressive financial results for its second quarter of fiscal year 2026, concluded on July 31, 2025. These results emphasize the company's robust performance and the increasing demand for advanced AI solutions across various sectors.

Revenue Growth and Key Metrics

During the second quarter, Ambarella reported a remarkable revenue of $95.5 million. This figure reflects a significant increase of 49.9% compared to the $63.7 million achieved in the same quarter of fiscal year 2025. Over the first six months of the fiscal year, revenue reached $181.4 million, marking an impressive 53.5% rise from the previous year’s corresponding period, which recorded $118.2 million.

Profitability and Margins

The company's gross margin under U.S. GAAP for Q2 2026 was 58.9%, a slight decline from 60.8% in the same period last year. For the six months ending July 31, 2025, the gross margin stood at 59.4%, down from 60.8% year-over-year. This margin contraction is attributed to various factors, including increased operational costs associated with expanding product lines.

Net Loss Reduction

Ambarella recorded a net loss of $20.0 million for the second quarter, equating to a loss of $0.47 per diluted share, an improvement from the $34.9 million loss, or $0.85 per share, in Q2 of fiscal 2025. For the six months ended July 31, 2025, the total loss was $44.3 million, indicating a notable reduction from a loss of $72.8 million during the same period last year.

Non-GAAP Performance Overview

On a non-GAAP basis, which excludes certain costs, Ambarella reported a gross margin of 60.5% for Q2 2026 compared to 63.3% in Q2 2025. The non-GAAP net profit was $6.4 million, or $0.15 per diluted share, a substantial turnaround from a $5.5 million loss, or $0.13 per diluted share, in the prior year. For the first half of the fiscal year, the non-GAAP net profit was $9.5 million, contrasting with a loss of $16.0 million in the same timeframe the previous year.

Guidance and Future Outlook

Looking ahead, Ambarella has set ambitious targets for the third quarter of fiscal year 2026, projecting revenue between $100.0 million and $108.0 million. The expected non-GAAP gross margin is anticipated to be in the range of 60.0% to 61.5%, while the operating expenses are forecasted to lie between $54.0 million and $57.0 million. This projection demonstrates Ambarella's confidence in its growth within the edge AI market.

Market Position and Innovations

Ambarella's strong performance in the edge AI sector is fueled by the constant evolution of its products. The company is actively pursuing growth opportunities with higher end 5nm AI system-on-chips (SoCs) catering to diverse applications, including AI-driven video and robotics. Currently, over 36 million edge AI processors have been shipped, solidifying Ambarella's status as a key player in this fast-growing industry.

Fermi Wang, President and CEO, expressed enthusiasm regarding the ongoing expansion. He stated, "Our commitment remains firmly focused on meeting our customers' needs, especially in areas like automotive and edge infrastructure, which are projected to yield significant opportunities in the upcoming years." He further noted expectations for production shipments from innovative products, including their first robotic aerial drone, anticipated for the end of fiscal year 2026.

Quarterly Conference Call

Ambarella will host a conference call to discuss the second quarter results today with top executives. The call will detail the company’s strategic roadmap and financial outlook, providing stakeholders with insights into the company’s performance and future direction.

About Ambarella

Ambarella specializes in advanced semiconductor solutions tailored for various applications in edge AI and human vision technology. From video security to automotive applications, the company’s low-power systems-on-chips (SoCs) are at the forefront of enabling intelligent perception, image processing, and advanced analytics, supporting the accelerating shift toward AI-driven solutions.

Frequently Asked Questions

What were Ambarella's total revenues for Q2 2026?

Ambarella's total revenues for Q2 2026 reached $95.5 million, a 49.9% increase from the same period last year.

How did the company's net income change in Q2 2026?

In Q2 2026, Ambarella reported a net loss of $20.0 million, which is an improvement from a net loss of $34.9 million in Q2 2025.

What is the projected revenue range for Q3 2026?

Ambarella anticipates revenue between $100.0 million and $108.0 million for Q3 2026.

How many edge AI processors has Ambarella shipped to date?

To date, Ambarella has shipped over 36 million edge AI processors.

What industries are benefiting from Ambarella's technology?

Ambarella's semiconductor solutions are used across industries such as automotive, robotics, video security, and advanced driver assistance systems (ADAS).

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 313

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 193

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 128

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 130

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 224

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 332

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 134

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 541

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 161

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Phreesia Announces Q3 Fiscal Year 2025 Financial Results

Updated Category News Views 71

Phreesia to Release Fiscal Q3 2025 Results Soon Phreesia, Inc. (NYSE: PHR) has great news for its stakeholders! The company revealed plans to announce its financial results for the third quarter of fiscal year 2025 right after market closing on a Monday in December. During this quarter, the firm experienced substantial growth and is eager to share the details with the...

Continue Reading
Innovative Water Bowl Design Enhances Pet Hydration Experience

Updated Category News Views 374

Revolutionary Pet Water Bowl Crafted for Optimal Hydration Every pet owner knows the importance of keeping their furry friends hydrated, especially during hot days. A new invention promises to enhance the experience for pets and their owners alike. This innovative water bowl, known as the THERMA DRINK, is designed with features that cater directly to pet needs. The idea...

Continue Reading
HPH's Leadership Changes Signify Strategic Direction Ahead

Updated Category News Views 177

Leadership Transitions at HPH Highest Performances Holdings Inc. (NASDAQ: HPH) has recently seen a notable change in its Board of Directors. The company announced that Mr. Peh Chin Hua's tenure as Director has come to an end, effective immediately. This decision is part of a broader strategy aimed at strengthening the Board's overall composition and capabilities. Current...

Continue Reading
Apranga Group Reports Growth in Retail Turnover for 2025

Updated Category News Views 132

Apranga Group Retail Performance Overview for 2025 Apranga Group, a major player in the retail sector, has announced its impressive financial performance for the first six months of 2025, demonstrating notable growth compared to the prior year. The company's retail turnover reached a commendable EUR 166.1 million, reflecting a 2.8% increase from the same period in 2024....

Continue Reading
IMUNON Unveils Promising New Vaccine Data for COVID-19

Updated Category News Views 154

New Vaccine Insights from IMUNON's Phase 1 Clinical Trial The innovative PlaCCine technology platform developed by IMUNON, Inc. (NASDAQ: IMNN) promises remarkable durability and advantages over traditional mRNA vaccines, particularly in the struggle against COVID-19. Robust Results from IMNN-101 Vaccine Trials In an encouraging announcement, IMUNON shared pivotal data...

Continue Reading